The work of Professor Jeffrey Cummings, a member of Sydney-based biotechnology company Actinogen Medical’s clinical advisory board, was recognised with a Lifetime Achievement Award at the recent Alzheimer’s Association International Conference (AAIC) 2018 in Chicago.
The award is presented to honour individuals who have made a significant scientific contribution and lifetime commitment to progress the fight against Alzheimer’s disease and dementia.
Actinogen says Professor Cummings is a founding member of its clinical advisory board and continues to provide invaluable advice and research expertise to the company in its development of the drug Xanamem in the fight against Alzheimer’s disease.
The AAIC is promoted as the world’s largest conference for researchers focused on investigating and developing treatments for Alzheimer’s. Its awards recognise the efforts and contributions of researchers who have furthered the understanding of Alzheimer’s disease.
Professor Cummings founded the Cleveland Clinic Lou Ruvo Centre for Brain Health in the US cities of Las Vegas and Cleveland. He is currently the principal investigator and director of the Centre for Neurodegeneration and Translational Neuroscience (a collaborative enterprise between the Lou Ruvo Centre and University of Nevada Las Vegas), and the founding director of the UCLA Alzheimer’s Disease Research Centre.
“Having one of our advisory board members receive such a prestigious award reflects the exceptional calibre of internationally recognised academic experts supporting Actinogen’s development of Xanamem,” Actinogen Medical CEO Dr Bill Ketelbey said.
“Jeff is a renowned Alzheimer’s researcher and has devoted much of his life to researching and developing treatments to fight against this devastating disease. No one deserves this award more than Jeff and we’re delighted to have his intellect and research expertise to advise on the development of Xanamem.”
